A Phase 2 interventional study of SNG001 and Placebo in SARS-CoV-2, sponsored by Synairgen Research Ltd.. Completed at 13 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-04.
Sponsored by Synairgen Research Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Interferon beta-1a in COVID-19 — 1 open to participants now, 1 under way, 1 of them phase 3. Interferon beta-1a · COVID-19.
Among the 12 studies testing Interferon beta-1a in COVID-19, this one is the 7th largest by enrollment, is one of 8 that started in 2020, is one of 4 in phase 2, and was the 5th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →1 of the 12 studies testing Interferon beta-1a in COVID-19 is open now, in 12 countries. Recruiting first, the newest first:
UMC Utrecht · Sites in United States, Australia, Belgium and 26 more countries
Ages 28 days+
By country, each count listing its studies:
Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 6 · Phase 4 1
First in 2016; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 221 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 422 across the 12 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 8 most frequent:
Synairgen Research Ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Synairgen Research Ltd. has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing Interferon beta-1a in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
SNG001 is an inhaled drug that contains a antiviral protein called interferon beta (IFN-β). IFN-β in produced in the lungs during viral lung infections. It has been shown that older people and people with some chronic diseases have an IFN-β deficiency. Many viruses inhibit IFN-β as part of their strategy to evade the immune system.
Addition of IFN-β in vitro protects lung cells from viral infection. IFN-β protects cells against the MERS and SARS coronaviruses (close relatives of SARS-CoV-2, the virus that causes COVID-19).
SNG001 is an inhaled formulation of interferon beta-1a it is currently in Phase II clinical trials for COPD patients.
Synairgen has conducted randomised placebo controlled clinical trials of SNG001 involving >200 asthma and COPD patients. These trials have shown that SNG001 has:
Synairgen believes SNG001 could help prevent worsening or accelerate recovery of severe lower respiratory tract illness in COVID-19 patients.
Patients who are in hospital or non-hospitalised but are a high risk groups (e.g. elderly or diabetics) will be invited to take part in the trial. The patient would receive either SNG001 or placebo once daily for 14 days. The severity of the patients condition would be recorded on a scale developed by the World Health Organisation and the patient would be asked questions about their breathlessness, cough and sputum every day, as well as assess their general medical condition and safety.
The study will start as a Pilot phase where 100 patients will be randomised in the hospital setting and a 120 patients randomised in the home setting.
Once each of the Pilot phases are complete, a Pivotal phase will be conducted. It is estimated that the size of each of the Pivotal phases (hospital and home) will be around 100 to 300 patients per arm. The actual number will be determined after the data review at the end of each of the Pilot phases.
If SNG001 proves to be beneficial it would be a major breakthrough for the treatment of COVID-19.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A. Hospital setting: positive virus test for SARS-CoV-2 using RT-PCR, or positive point-of-care viral infection test in the presence of strong clinical suspicion of SARS-CoV-2 infection.
B. Home setting: positive virus test for SARS-CoV-2 using a molecular assay e.g. RT-PCR in the presence of strong clinical suspicion of SARS-CoV-2 infection.
A. Hospital setting: patients admitted to hospital due to the severity of their COVID 19 disease OR
B. Home setting: non-hospitalised patients from high-risk groups, defined as ≥65-years of age, or ≥50 years of age and with any of the following risk factors:
B. Home setting: non-hospitalised female patients must be ≥1 year post-menopausal or surgically sterile.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
inhalation using the I-neb device.
Drug: SNG001
inhalation using the I-neb device.
Drug: Placebo
Drug pages: Interferon beta-1a · Interferon Beta-1a Inhalation Solution SNG001
SNG001 via inhalation
Placebo via inhalation
Ordinal Scale for Clinical Improvement
Change in condition measured using the Ordinal Scale for Clinical Improvement during the dosing period - minimum of 0 (patient is well) to a maximum of 8 (death)
Time frame: Day 1 to Days 15 and 28
Progression to pneumonia (hospital setting only)
Progression to pneumonia as diagnosed by chest x-ray, if no pneumonia is present at time of enrolment
Time frame: Day 2 to Day 28
Progression to pneumonia (hospital setting only)
Evolution of pneumonia, as diagnosed by chest x-ray, if pneumonia is present at time of enrolment
Time frame: Day 1 to Day 28
Time to clinical improvement (hospital setting only)
Time to clinical improvement
Time frame: Time to hospital discharge OR Time to NEWS2 of ≤ 2 maintained for 24 hours
National Early Warning Score 2 (NEWS2) assessment of acute-illness severity (hospital setting only)
NEWS2 assessment of acute-illness severity on a scale of 0 ( being well) up to 24 (requiring emergency response)
Time frame: Day 1 to Day 28
Changes in daily breathlessness, cough and sputum scale (BCSS)
Changes in daily breathlessness, cough and sputum scale (BCSS) on a scale of 0 (no symptoms) up to 4 (severe symptoms)
Time frame: Day 1 to Day 28 (and Day 60 and 90 home setting only)
Safety and tolerability - blood pressure (hospital setting only)
Looking at blood pressure measured in mmHg
Time frame: Day 1 to Day 15
Safety and tolerability - heart rate
Looking at heart rate measured in beats per minute
Time frame: Day 1 to Day 15
Safety and tolerability - temperature
Looking at temperature measured in degrees Celsius
Time frame: Day 1 to Day 15
Safety and tolerability - respiratory rate (hospital setting only)
Looking at respiratory rate measure in breaths per minute
Time frame: Day 1 to Day 15
Safety and tolerability - oxygen saturation
Looking at oxygen levels measured in a %
Time frame: Day 1 to Day 15
Safety and tolerability - adverse events
Looking at adverse events (numbers and terms)
Time frame: Day 1 to Day 28
Safety and tolerability - concomitant medications
Looking at concomitant medications given during treatment
Time frame: Day 1 to Day 28
Time to clinical improvement (home setting only)
Temperature ≤37.8 °C AND COVID-19 symptoms (breathing, cough, sputum, muscle aches, headache, fatigue, sore throat, loss or change to sense of smell and taste, rhinorrhoea and anorexia) all rated as absent or mild
Time frame: Day 1 to Day 15
Time to improvement of COVID-19 symptoms (home setting only).
Time to improvement of COVID-19 symptoms (fever, breathing, cough, sputum, muscle aches, headache, fatigue, sore throat, loss or change to sense of smell and/or taste, rhinorrhoea and anorexia)
Time frame: Day 1 to Day 28 and Day 60 and 90
Time to self-reported recovery (home setting only)
Time to self-reported recover
Time frame: Day 2 to Day 15 and Day 28, 60 and 90
Self-reported daily rating of overall feeling of wellness (home setting only).
Self-reported daily rating of overall feeling of wellness scale from 1 (the worst you can imagine) to 10 (the best you can imagine)
Time frame: Day 1 to Day 28 and Day 60 and 90
Quality of life measured using EQ-5D-5L (home setting only).
Quality of life measured using EQ-5D-5L - 5 questions where minimum score is 1 (best outcome) to 5 (worst outcome), visual analogue scale is also included for this 100 is best health you can imagine to 0 worst health you can imagine
Time frame: Day 1 to Day 28 and Day 60 and 90
Virus clearance/load (if samples are available)
Time to virus clearance and viral load
Time frame: Day 1 to Day 28
Blood and sputum biomarkers (if samples are available).
Blood and sputum biomarkers
Time frame: Day 1 to Day 28
Contact with health services (home setting only)
Contact with health services
Time frame: Day 1 to Day 28
Consumption of antibiotics (home setting only)
Consumption of antibiotics
Time frame: Day 1 to Day 28
General Anxiety Disorder 7 (home setting only)
Assessment of anxiety - score of 0 (best) to 3 (worst)
Time frame: Day 60 and 90
Patient Health Questionnaire - 9
Assessment of mental health - score of 0 (best) to 3 (worst)
Time frame: Day 60 and 90
FACIT Fatigue Scale
Assessment of Fatigue - score of 0 (best) to 4 (worst)
Time frame: Day 60 and 90
Nottingham Extended Activities of Daily Living Scale
Assessment of activities of daily living - no score just tick the box that applies; 'Not at all', 'With help', 'On your own with difficulty' and 'On your own'
Time frame: Day 60 and 90
Plan to share: No — No plan to share data
Ran from Mar 2020 to primary completion in Feb 2021, 11 months.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 11 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Interferon beta-1a · Interferon Beta-1a Inhalation Solution SNG001
Synairgen Research Ltd.